Piazza Statuto, 18
Contatto: Marco Dieci
Ruolo: Chief Operating Officer
Telefono: 345 8049292
Sito web: www.evobiotech.it
Numero di impiegati: 4
Anno costituzione: 2019
Settori di attività: pharma, biopharma, nutraceutica, biotech healthcare, healthcare, cosmetics
Who we are ?
EvoBiotech is an emerging company focused on developing a technology platform based on plant-derived extracellular vesicles. It was founded in 2019 by a team of experts in the extracellular vesicles field, with the aim of leading to the clinical application of plant-derived extracellular vesicles and offering more efficient and easy-to-use treatment options to patients and caregivers.
EvoBiotech was founded by four members of the major Italian research group specialized in the study of extracellular vesicles and their application in the field of regenerative medicine. In fact, the biomedical research team is run by Professor Giovanni Camussi, a leading expert on stem cells and a worldwide pioneer in the research on extracellular vesicles. Their first discovery goes back to 2007, when Professor Camussi and Dr. Deregibus demonstrated that extracellular vesicles act as mediators in the exchange of information between cells.
Our research is focused on a new source of extracellular vesicles: edible plants. Plant extracellular vesicles have extraordinary intrinsic biological properties, which make them an ideal tool to evolve current treatments.
Using plants as a source for extracellular vesicles, we can overcome several limitations of other starting materials, such as human cells, especially in terms of yield, costs, and manufacturing time, but also in terms of safety. Plant extracellular vesicles can be easily used to improve therapeutic efficacy and/or drug delivery in clinical applications.
What we do ?
Extracellular vesicles are bioactive nanoparticles released by all kind of cells. They are composed by several molecules, including lipids, proteins and nucleic acids. Extracellular vesicles act as messengers between cells, transferring bioactive molecules from donor cells to recipient cells and modulating cell behaviour.
Extracellular vesicles derived from plant represent a new emerging technology with several advantages. They can be manufactured using a scalable extractive method that produces concentrated preparations of extracellular vesicles. Moreover, Plant extracellular vesicles can be easily administered using almost all routes (enteral, parenteral and intranasal).
Plant extracellular vesicles show extraordinary features which make them attractive as an innovative solution for human therapy. We are developing new therapeutic solutions by exploiting different properties of extracellular vesicles, mainly focused on two therapeutic areas: wound care and drug delivery.